Answers to Common Misconceptions Regarding the Toxicity of Aluminum Adjuvants in Vaccines

Tomljenovic, Lucija; Shaw, Christopher A.

doi:10.1002/9781118663721.ch4

Vaccines and Autoimmunity 2015

DOI: 10.1002/9781118663721.ch4

|View full text |Cite

Answers to Common Misconceptions Regarding the Toxicity of Aluminum Adjuvants in Vaccines

Lucija Tomljenovic

Christopher A. Shaw

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant

Euliano,

Pogostin,

Agrawal

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Toll‐like receptors (TLRs) recognize pathogen‐ and damage‐associated molecular patterns and, in turn, trigger the release of cytokines and other immunostimulatory molecules. As a result, TLR agonists are increasingly being investigated as vaccine adjuvants. Many of these agonists are small molecules that quickly diffuse away from the vaccination site, limiting their co‐localization with antigens and, thus, their effect. Here, the small‐molecule TLR7 agonist 1V209 is conjugated to a positively‐charged multidomain peptide (MDP) hydrogel, K2, which was previously shown to act as an adjuvant promoting humoral immunity. Mixing the 1V209‐conjugated K2 50:50 with the unfunctionalized K2 produces hydrogels that retain the shear‐thinning and self‐healing physical properties of the original MDP while improving the solubility of 1V209 more than 200‐fold compared to the unconjugated molecule. When co‐delivered with ovalbumin as a model antigen, 1V209‐functionalized K2 produces a robust Th2 immune response and an antigen‐specific Th1 immune response superior to alum, a widely used vaccine adjuvant. Together, these results suggest that K2 MDP hydrogels functionalized with 1V209 are a promising adjuvant for vaccines against infectious diseases, especially those benefiting from a combined Th1 and Th2 immune response.

show abstract

A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant

Euliano,

Pogostin,

Agrawal

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

Multidomain peptide hydrogel adjuvants elicit strong bias towards humoral immunity

Pogostin

Azares³

et al. 2022

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Rabies virus protection issues and therapy

Dodds¹

2016

Glob Vaccines Immunol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Answers to Common Misconceptions Regarding the Toxicity of Aluminum Adjuvants in Vaccines

Cited by 5 publications

References 105 publications

A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant

A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant

Multidomain peptide hydrogel adjuvants elicit strong bias towards humoral immunity

Rabies virus protection issues and therapy

Contact Info

Product

Resources

About